Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q2 2013 · 10-Q
Revenue$7.08M$7.08M−42.7% vs Q2 2012 Net Income-$639.02K-$639.02KN/M vs Q2 2012 EPS Diluted-$0.03-$0.03N/M vs Q2 2012 Operating Income-$1,140,544N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$113,466−76.8% Margins · derivedOperating margin-16.1%−31.8 pt vs Q2 2012
Net margin-9.0%−23.1 pt vs Q2 2012
ended Jun 30, 2013 · filed Aug 9, 2013 · 40 d after period end